Literature DB >> 21531886

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.

George L Bakris1.   

Abstract

Nephropathy is a common microvascular complication among patients with type 2 diabetes mellitus and a major cause of kidney failure. It is characterized by albuminuria (≥ 300 mg/d) and a reduced glomerular filtration rate and is often present at the time of diabetes diagnosis after the kidney has been exposed to chronic hyperglycemia during the prediabetic phase. A low glomerular filtration rate (<60 mL/min/1.73 m(2)) is also an independent risk factor for cardiovascular events and death. Detection of diabetic nephropathy during its initial stages provides the opportunity for early therapeutic interventions to prevent or delay the onset of complications and improve outcomes. An intensive and multifactorial management approach is needed that targets all risk determinants simultaneously. The strategy should comprise lifestyle modifications (smoking cessation, weight loss, increased physical activity, and dietary changes) coupled with therapeutic achievement of blood glucose, blood pressure, and lipid goals that are evidence-based. Prescribing decisions should take into account demographic factors, level of kidney impairment, adverse effects, risk of hypoglycemia, tolerability, and effects on other risk factors and comorbidities. Regular and comprehensive follow-up assessments with appropriate adjustment of the therapeutic regimen to maintain risk factor control is a vital component of care, including referral to specialists, when required.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531886      PMCID: PMC3084647          DOI: 10.4065/mcp.2010.0713

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  116 in total

1.  Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients.

Authors:  Wing Yee So; Alice P S Kong; Ronald C W Ma; Risa Ozaki; Cheuk Chun Szeto; Norman N Chan; Vanessa Ng; Chung Shun Ho; Christopher W K Lam; Chun Chung Chow; Clive S Cockram; Juliana C N Chan; Peter C Y Tong
Journal:  Diabetes Care       Date:  2006-09       Impact factor: 19.112

2.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Heterogeneous nature of renal lesions in type II diabetes.

Authors:  V Gambara; G Mecca; G Remuzzi; T Bertani
Journal:  J Am Soc Nephrol       Date:  1993-02       Impact factor: 10.121

Review 5.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

6.  Frequency of hypoglycemia and its significance in chronic kidney disease.

Authors:  Maureen F Moen; Min Zhan; Van Doren Hsu; Lori D Walker; Lisa M Einhorn; Stephen L Seliger; Jeffrey C Fink
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

7.  Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes.

Authors:  Temduang Chuahirun; Jan Simoni; Cathy Hudson; Timothy Seipel; Apurv Khanna; Ronald B Harrist; Donald E Wesson
Journal:  Am J Med Sci       Date:  2004-02       Impact factor: 2.378

8.  Nonalbuminuric renal insufficiency in type 2 diabetes.

Authors:  Richard J MacIsaac; Con Tsalamandris; Sianna Panagiotopoulos; Trudy J Smith; Karen J McNeil; George Jerums
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

9.  Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.

Authors:  Riza C Ozsoy; Wim A van der Steeg; John J P Kastelein; Lambertus Arisz; Marion G Koopman
Journal:  Nephrol Dial Transplant       Date:  2007-03-08       Impact factor: 5.992

Review 10.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.

Authors:  M R Law; J K Morris; N J Wald
Journal:  BMJ       Date:  2009-05-19
View more
  55 in total

1.  An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-08-15       Impact factor: 4.009

2.  Investigation of the influence of nephropathy on monoclonal antibody disposition: a pharmacokinetic study in a mouse model of diabetic nephropathy.

Authors:  Frank A Engler; Bo Zheng; Joseph P Balthasar
Journal:  Pharm Res       Date:  2013-11-08       Impact factor: 4.200

3.  Diabetic nephropathy in Africa: A systematic review.

Authors:  Jean Jacques N Noubiap; Jashira Naidoo; Andre P Kengne
Journal:  World J Diabetes       Date:  2015-06-10

4.  Zinc status in type 2 diabetic patients: relation to the progression of diabetic nephropathy.

Authors:  Dhia J Al-Timimi; Dhia M Sulieman; Kajeen R Hussen
Journal:  J Clin Diagn Res       Date:  2014-11-20

5.  Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat.

Authors:  Gurkishan S Chadha; Marilyn E Morris
Journal:  AAPS J       Date:  2015-04-30       Impact factor: 4.009

6.  GSK-3β function in bone regulates skeletal development, whole-body metabolism, and male life span.

Authors:  J R Gillespie; J R Bush; G I Bell; L A Aubrey; H Dupuis; M Ferron; B Kream; G DiMattia; S Patel; J R Woodgett; G Karsenty; D A Hess; F Beier
Journal:  Endocrinology       Date:  2013-07-31       Impact factor: 4.736

7.  [Dexmedetomidine hydrochloride up-regulates expression of hypoxia inducible factor-1α to alleviate renal ischemiareperfusion injury in diabetic rats].

Authors:  Zhonghua Ji; Liping Wang; Shiying Wang; Genqiang Liang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-08-30

Review 8.  Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.

Authors:  Carlo B Giorda; Elisa Nada; Barbara Tartaglino
Journal:  Endocrine       Date:  2014-02-08       Impact factor: 3.633

9.  Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.

Authors:  Baptist Gallwitz
Journal:  Ther Adv Endocrinol Metab       Date:  2013-06       Impact factor: 3.565

10.  Dialysis and fatigue: implications for nurses--a case study analysis.

Authors:  Ann Horigan; Judith Rocchiccioli; Donna Trimm
Journal:  Medsurg Nurs       Date:  2012 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.